You are here: Industry Insights > Direct Biologics

News List

ExoFlo™ From Direct Biologics Fulfills Urgent Medical Need in COVID-19 Treatment prnasia
July 21, 2021
As intensive care units across the country fill to capacity, hospital beds are in dangerously short supply, and deaths from COVID-19 continue to spike, doctors from medical centers coast to coast are reporting on the remarkable healing properties of ...
Direct Biologics Announces FDA Approval for Proceeding With Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome prnasia
July 21, 2021
Direct Biologics announced today that it has received FDA approval to initiate a Phase I/II trial under an Investigational New Drug (IND) protocol for the use of ExoFlo™ in the treatment of Post-Acute COVID-19 Syndrome.
Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome prnewswire
July 15, 2021
Direct Biologics announced today that the U.S Food and Drug Administrationhas approved its Investigational New Drug (IND) application to conduct a Phase I/II clinical trial using ExoFlo™ in the treatment of Acute Respiratory Distress Syndrome (ARDS).
Direct Biologics Initiates Patient Enrollment in EXIT COVID-19 Clinical Trial ExoFlo americanpharmaceuticalreview
September 15, 2020
Direct Biologics announced the launch of EXIT COVID-19, their Phase II, multi-center clinical trial examining the use of ExoFlo™ extracellular vesicles to treat COVID-19 associated acute respiratory distress syndrome (ARDS).
Direct Biologics Receives FDA Approval to Initiate “EXIT-COVID-19” Drug Trial americanpharmaceuticalreview
August 06, 2020
Direct Biologics has received approval from FDA that it may proceed with a Phase II trial under an Investigational New Drug (IND) application for the use of ExoFlo™, a bone marrow-derived extracellular vesicle and exosome product, in the treatment of ...
M&As this week: Sinclair Pharma, Direct Biologics pharmaceutical-technology
November 25, 2018
The deal will enable Sinclair to expand its product pipeline for minimally invasive treatments and build partnerships with aesthetic physicians and organisations in the US.